Leukemia
1,656
99
140
1,053
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
376 trials with published results (23%)
Research Maturity
1053 completed trials (64% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.1%
217 terminated out of 1656 trials
82.9%
-3.6% vs benchmark
9%
154 trials in Phase 3/4
36%
376 of 1053 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1053 completed trials
Clinical Trials (1656)
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Integrated Cancer Repository for Cancer Research
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
Case-Control Study of Pesticides and Childhood Leukemia
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Weight Gain in Pediatric Leukemia Survivors
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Managed Access Programs for CTL019, Tisagenlecleucel
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia